Table 1

Patients' features

KRAS wild-type, no. (%)

KRAS mutant, no. (%)

Total no. (%)


No. of patients

31 (53)

28 (47)

59

Male/female

21/10

16/12

37/22

Age, years:

Median

64

65

63

Range

42 to 73

48 to 73

42 to 73

≥65

13 (42)

13 (46)

26 (44)

WHO performance status:

0

28 (90)

26 (93)

54 (92)

1 to 2

3 (10)

2 (7)

5 (8)

Metastatic disease:

Metachronous

10 (32)

7 (25)

17 (29)

Synchronous

21 (68)

21 (75)

42 (71)

Primary tumor:

Colon

14 (45)

20 (71)

34 (58)

Rectum

17 (55)

8 (29)

25 (42)

Sites of metastases:

Liver

19 (61)

20 (71)

39 (66)

Lung

7 (23)

5 (18)

12 (20)

Lymph nodes

10 (32)

8 (29)

18 (30)

Local

6 (19)

3 (11)

9 (15)

Other

2 (6)

6 (21)

8 (14)

No. of involved sites:

1

17 (55)

17 (61)

34 (58)

≥2

14 (45)

11 (39)

25 (42)

Single metastatic sites:

Liver limited

12 (39)

13 (46)

25 (42)

Other than liver

7 (22)

4 (15)

11 (19)

Lung

2 (6)

2 (7)

4 (7)

Lymph nodes

2 (6)

1 (4)

3 (5)

Local

3 (10)

1 (4)

4 (7)

Multiple metastatic sites

12 (39)

11 (39)

23 (39)

Liver metastases:

Single

8 (26)

3 (11)

11 (19)

Multiple

11 (35)

11 (39)

22 (37)

Previous adjuvant chemotherapy:

6 (19)

2 (7)

8 (14)

FA/5-FU bolus

3 (10)

-

3 (5)

Capecitabine

-

-

-

FOLFOX4

2 (6)

2 (7)

4 (7)

XelOx

1 (3)

-

1 (2)

Previous radiotherapy:

4 (13)

1 (4)

5 (8)

Radiotherapy alone

-

-

-

Radiotherapy + chemotherapy (5-FU continuous infusion)

2 (6)

-

2 (3)

Radiotherapy + chemotherapy (XELOX)

2 (6)

1 (4)

3 (5)


WHO = World Health Organization.

Bruera et al. BMC Medicine 2012 10:135   doi:10.1186/1741-7015-10-135

Open Data